SCHEMBL20073653

SCHEMBL20073653

Cc1ccc(C(C)C)c(N(C)S(C)(=O)=O)c1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.43
TRPA1 O75762 1/20 0.43
CHRM1 P11229 1/20 0.43
SLC6A2 P23975 1/20 0.43
ADRA1A P35348 1/20 0.43
HTR2B P41595 1/20 0.43
ALDH1A1 P00352 4/20 0.40
HPGD P15428 1/20 0.40
CYP19A1 P11511 2/20 0.38
KDM4E B2RXH2 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
NPSR1 Q6W5P4 1/20 0.37
AKR1B1 P15121 1/20 0.36
GAA P10253 2/20 0.35
C5AR1 P21730 1/20 0.35
HTT P42858 1/20 0.35
HSP90AA1 P07900 1/20 0.34
HSP90AB1 P08238 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24497546 0.83 AKR1B1 (0.43) LMNATRPA1CHRM1SLC6A2ADRA1A
SCHEMBL24497708 0.83 CYP19A1 (0.38) LMNATRPA1ALDH1A1HPGDCYP19A1
SCHEMBL2737239 0.81 PSEN1 (0.41) ALDH1A1HPGDCYP19A1KMT2A
SCHEMBL20073675 0.81 HTT (0.42) LMNAALDH1A1HPGDCYP19A1KDM4E
SCHEMBL24497547 0.81 CYP19A1 (0.37) LMNAALDH1A1HPGDCYP19A1HSP90AA1
SCHEMBL24498236 0.80 LMNA (0.38) LMNATRPA1CHRM1SLC6A2ADRA1A
SCHEMBL24498140 0.79 CYP19A1 (0.40) LMNAALDH1A1CYP19A1GAAKMT2A
SCHEMBL20150117 0.79 ALDH1A1 (0.37) LMNAALDH1A1HPGDCYP19A1KMT2A
SCHEMBL21375770 0.78 LMNA (0.48) LMNAALDH1A1CYP19A1NPSR1AKR1B1
SCHEMBL24497565 0.78 CYP19A1 (0.46) LMNAALDH1A1HPGDCYP19A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022117016-A1 HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 深圳微芯生物科技股份有限公司 2022-06-09 WO disclosed
US-20220073527-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-03-10 US disclosed
EP-3848370-A2 TYK2 INHIBITORS AND USES THEREOF Nimbus Lakshmi, Inc. (US) 2021-07-14 EP disclosed
US-20210094948-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-04-01 US disclosed
US-10647713-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2020-05-12 US disclosed
US-20180134700-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-05-17 US disclosed
WO-2018075937-A1 TYK2 INHIBITORS AND USES THEREOF NIMBUS LAKSHMI, INC. (US) 2018-04-26 WO disclosed
WO-2018071794-A1 TYK2 INHIBITORS AND USES THEREOF NIMBUS LAKSHMI, INC. (US) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210094948-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 LMNA 2078/4885TRPA1 4793/4885CHRM1 4839/4885
US-20180134700-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 LMNA 2078/4885TRPA1 4793/4885CHRM1 4839/4885
US-10647713-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 LMNA 2078/4885TRPA1 4793/4885CHRM1 4839/4885
US-20220073527-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 LMNA 2078/4885TRPA1 4793/4885CHRM1 4839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.